Cencora (NYSE:COR) Updates FY 2025 Earnings Guidance

Cencora (NYSE:COR - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 15.150-15.450 for the period, compared to the consensus earnings per share estimate of 14.980. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on COR. Barclays increased their price target on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Wells Fargo & Company dropped their price target on Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a research report on Friday, December 13th. Robert W. Baird lifted their price objective on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Finally, Evercore ISI lifted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $275.60.

Cencora Price Performance

Shares of COR stock traded up $0.06 on Thursday, reaching $224.74. The company's stock had a trading volume of 736,708 shares, compared to its average volume of 1,374,561. The company has a market capitalization of $43.44 billion, a P/E ratio of 29.93, a PEG ratio of 1.54 and a beta of 0.45. Cencora has a 12-month low of $207.63 and a 12-month high of $253.27. The stock's 50 day simple moving average is $237.54 and its 200-day simple moving average is $233.66. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio (DPR) is 29.29%.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares in the company, valued at approximately $74,283,064.32. This represents a 6.55 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 94,696 shares of company stock worth $22,862,734. Insiders own 15.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.